Celebrating a year of immunotherapy/cell and gene therapy in Blood Advances.
作者信息
Bollard Catherine M, Weyrich Andrew S
出版信息
Blood Adv. 2024 Dec 24;8(24):6334-6336. doi: 10.1182/bloodadvances.2024015305.
Abstract
摘要
相似文献
1
Celebrating a year of immunotherapy/cell and gene therapy in Blood Advances.庆祝《血液进展》中免疫疗法/细胞与基因疗法的一年。
Blood Adv. 2024 Dec 24;8(24):6334-6336. doi: 10.1182/bloodadvances.2024015305.
2
Celebrating a decade of the .庆祝……的十年。
你提供的原文不完整，请补充完整以便我准确翻译。
J Immunother Cancer. 2022 May;10(5). doi: 10.1136/jitc-2022-005207.
3
Celebrating the 15th anniversary of : a reflection on 2022.庆祝……十五周年：对2022年的回顾。
（你提供的原文中“Celebrating the 15th anniversary of :”这里“of”后面缺少具体内容，我按照常规理解翻译了后半句。）
Immunotherapy. 2023 Jan;15(1):1-4. doi: 10.2217/imt-2022-0291. Epub 2023 Jan 26.
4
Celebrating a year of clinical and translational research in Blood Advances.庆祝《血液进展》临床与转化研究的一年。
Blood Adv. 2022 Dec 27;6(24):6271-6273. doi: 10.1182/bloodadvances.2022009151.
5
Celebrating a year of cancer research in Blood Advances.《血液进展》中癌症研究成果丰硕的一年。
Blood Adv. 2023 Dec 26;7(24):7621-7623. doi: 10.1182/bloodadvances.2023011867.
6
Cancer and radiation therapy: current advances and future directions.癌症与放射治疗：当前进展与未来方向。
Int J Med Sci. 2012;9(3):193-9. doi: 10.7150/ijms.3635. Epub 2012 Feb 27.
7
The age of immunotherapy-Celebrating STEM CELLS' contribution to understanding mechanisms of immune system development and modulation.免疫疗法时代——颂扬干细胞对理解免疫系统发育和调节机制的贡献。
Stem Cells. 2020 Jan;38(1):4-5. doi: 10.1002/stem.3137.
8
: celebrating 10 years of publication.庆祝创刊十周年。
RSC Adv. 2021 Jul 9;11(39):24054-24056. doi: 10.1039/d1ra90127c. eCollection 2021 Jul 6.
9
Celebrating blood donors amid advances in blood transfusion.在输血技术进步的背景下赞颂献血者。
Lancet Haematol. 2023 Jun;10(6):e389. doi: 10.1016/S2352-3026(23)00129-1.
10
Allergic rhinitis and asthma: celebrating 100 years of immunotherapy.变应性鼻炎和哮喘：免疫治疗百年庆典。
Curr Opin Immunol. 2011 Dec;23(6):808-13. doi: 10.1016/j.coi.2011.07.015. Epub 2011 Aug 19.
本文引用的文献
1
The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas.T 细胞激活的规则：嵌合抗原受体 T 细胞和双特异性抗体在 B 细胞淋巴瘤中的现状。
Blood Adv. 2024 Sep 10;8(17):4700-4710. doi: 10.1182/bloodadvances.2021004535.
2
Safety and feasibility of third-party cytotoxic T lymphocytes for high-risk patients with COVID-19.第三方细胞毒性T淋巴细胞用于高危COVID-19患者的安全性和可行性。
Blood Adv. 2024 Aug 13;8(15):4113-4124. doi: 10.1182/bloodadvances.2024013344.
3
CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations.嵌合抗原受体 T 细胞毒性：从床边到实验室，新型毒性如何为实验室研究提供信息。
Blood Adv. 2024 Aug 27;8(16):4348-4358. doi: 10.1182/bloodadvances.2024013044.
4
CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy.表达 IL-15 的 CD70 特异性 CAR NK 细胞用于治疗 CD19 阴性 B 细胞恶性肿瘤。
Blood Adv. 2024 Jun 11;8(11):2635-2645. doi: 10.1182/bloodadvances.2023012202.
5
Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia.嵌合抗原受体 T 细胞回输预防和治疗儿童急性淋巴细胞白血病复发。
Blood Adv. 2024 May 14;8(9):2182-2192. doi: 10.1182/bloodadvances.2024012885.
6
Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma.套细胞淋巴瘤患者接受 CD19 CAR T 细胞治疗后的神经毒性的临床特征。
Blood Adv. 2024 Mar 26;8(6):1474-1486. doi: 10.1182/bloodadvances.2023011896.
7
Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic.解答临床中“医生，CAR-T疗法会引发癌症吗？”这一问题。
Blood Adv. 2024 Feb 27;8(4):895-898. doi: 10.1182/bloodadvances.2023012336.
8
Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study.利妥昔单抗和第三方 LMP 特异性 T 细胞治疗后对 EBV 的持久免疫力：一项儿童肿瘤学组研究。
Blood Adv. 2024 Mar 12;8(5):1116-1127. doi: 10.1182/bloodadvances.2023010832.
9
Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies.自体 CAR T 细胞制造失败和/或血液系统恶性肿瘤疗效的早期预测因素。
Blood Adv. 2024 Jan 23;8(2):337-342. doi: 10.1182/bloodadvances.2023011992.
10
Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial.抗 CD30 CAR T 细胞治疗 CD30+淋巴瘤的一过性反应和显著毒性：一项 1 期试验结果。
Blood Adv. 2024 Feb 13;8(3):802-814. doi: 10.1182/bloodadvances.2023011470.
Zotero 插件